Trial Profile

Prospective Evaluation of Potential Effects of Repeated Gadolinium-based Contrast Agent (GBCA) Administrations of the Same GBCA on Motor and Cognitive Functions in Neurologically Normal Adults in Comparison to a Non-GBCA Exposed Control Group

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 01 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gadobenic acid (Primary) ; Gadobutrol (Primary) ; Gadodiamide (Primary) ; Gadoterate-meglumine (Primary) ; Gadoteridol (Primary) ; Gadoxetate disodium (Primary)
Indications Breast cancer; Colorectal cancer; Liver cancer; Neuroendocrine tumours; Pancreatic cancer; Prostate cancer
Focus Adverse reactions
Acronyms ODYSSEY
Sponsors Bayer; Bracco; GE Healthcare; Guerbet

13 Apr 2021 Status changed from not yet recruiting to recruiting.
04 Feb 2021 Planned End Date changed from 1 Jul 2029 to 31 Dec 2028.
04 Feb 2021 Planned primary completion date changed from 1 Jul 2029 to 31 Dec 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com